0001171843-26-003459
SEC filingEdesa Biotech's Board approved issuing 90% of CEO Pardeep Nijhawan's monthly base salary as fully vested RSUs, up from 50%, under his amended employment agreement.
The Board of Directors approved a significant increase in the equity portion of CEO Pardeep Nijhawan's compensation, shifting from 50% to 90% of his monthly base salary into fully vested restricted share units. This adjustment, requested by Dr. Nijhawan himself, aligns with provisions in his Amended and Restated Employment Agreement dated August 4, 2023. The RSUs will be granted monthly based on 90% of his salary divided by the fair market value of common shares at month-end, conserving cash while providing equity incentives under the 2019 Equity Incentive Compensation Plan. The 10% cash component ensures compliance with local labor laws and tax withholding. For investors, this signals CEO alignment with shareholder interests through increased equity exposure, potentially reducing near-term cash burn amid biotech funding constraints, though full terms are detailed in the referenced 10-K exhibit.